SHIKARI® Pertuzumab ELISA (Q-PER)

This kit has been especially developed for the quantitative determination of Pertuzumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

All SHIKARI® ELISA kits are suitable for biosimilar work. All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

Please contact us at for specific academic pricing.

Background

Pertuzumab Drug Bank Accession Number is DB06366
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

More Details